Feb 23, 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
Feb 18, 2021
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
Feb 11, 2021
Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock
Feb 11, 2021
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
Feb 10, 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium(TM) 2021
Feb 01, 2021
Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium(TM) 2021
Jan 04, 2021
Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January
Dec 30, 2020
Protalix BioTherapeutics Issues 2020 Letter to Shareholders
Dec 30, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Nov 27, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
Oct 29, 2020
Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30
Oct 29, 2020
Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Oct 26, 2020
Protalix BioTherapeutics to Participate in Virtual Investor KOL Roundtable
Oct 22, 2020
Protalix BioTherapeutics to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on October 29, 2020
Sep 08, 2020
Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards
Sep 08, 2020
Protalix BioTherapeutics to Present in the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
Aug 24, 2020
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry Disease
Aug 11, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
Aug 10, 2020
Protalix BioTherapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
Aug 06, 2020
Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology Conference 2020